Evidence map›Paper›PMID 31740175›Full record

ReviewThe International journal on drug policy2021

A review of network simulation models of hepatitis C virus and HIV among people who inject drugs.

Meghan Bellerose, Lin Zhu, Liesl M Hagan, William W Thompson, Liisa M Randall, Yelena Malyuta, Joshua A Salomon, Benjamin P Linas

Open access · greenAbstract readReview
In one paragraph

Review in The International journal on drug policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. A Review of Network Models for HIV Spread.Journal of acquired immune deficiency syndromes (1999) · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Potential Impact of Frequent Testing for Hepatitis C Virus Among People Who Inject Drugs Toward Hepatitis C Elimination in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Meghan BellerosePrevention Policy Modeling Lab, Department of Global Health and Population, Harvard T. H. Chan School of Public Health, 90 Smith Street, Boston, MA 02120, United States. Electronic address: meghanebellerose@gmail.com.
Lin ZhuPrevention Policy Modeling Lab, Department of Global Health and Population, Harvard T. H. Chan School of Public Health, 90 Smith Street, Boston, MA 02120, United States.
Liesl M HaganDivision of Viral Hepatitis, U.S. Centers for Disease Control, United States.
William W ThompsonDivision of Viral Hepatitis, U.S. Centers for Disease Control, United States.
Liisa M RandallMassachusetts Department of Public Health, United States.
Yelena MalyutaPrevention Policy Modeling Lab, Department of Global Health and Population, Harvard T. H. Chan School of Public Health, 90 Smith Street, Boston, MA 02120, United States.
Joshua A SalomonPrevention Policy Modeling Lab, Department of Global Health and Population, Harvard T. H. Chan School of Public Health, 90 Smith Street, Boston, MA 02120, United States; Center for Health Policy / Center for Primary Care and Outcomes Research, Stanford University, United States.
Benjamin P LinasBoston Medical Center, Boston University School of Public Health, United States.
Harvard Global Health Institute · USCenters for Disease Control and Prevention · USBoston University · USMassachusetts Department of Public Health · USStanford University · US

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Utilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorderP30DA040500 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI ZACHARY Franklin MEISEL · 2015 to 2026
$20.7M
Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR01DA015612 · NIDA · STANFORD UNIVERSITY · PI OWENS, DOUGLAS K · 2002 to 2017
$9.4M
Researching Effective Strategies to Prevent Opioid Death (RESPOND)R01DA046527 · NIDA · BOSTON MEDICAL CENTER · PI Benjamin P. Linas · 2018 to 2026
$7.2M
Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR37DA015612 · NIDA · STANFORD UNIVERSITY · PI DOUGLAS K OWENS · 2019 to 2026
$6.3M
Economic Modeling for HIV, Viral Hepatitis, STD, TB and School HealthU38PS004644 · PS · HARVARD SCHOOL OF PUBLIC HEALTH · PI SALOMON, JOSHUA A · 2014 to 2015
$2.9M
Simulation Modeling to Improve HIV/HCV Screening, Treatment and CareR01DA031059 · NIDA · BOSTON MEDICAL CENTER · PI LINAS, BENJAMIN P. · 2012 to 2015
$2.1M
CDC HHSNCHHSTP CDC HHS U38 PS004644NIAID NIH HHS P30 AI042853NIDA NIH HHS P30 DA040500NIDA NIH HHS R01 DA015612NIDA NIH HHS R01 DA046527NIDA NIH HHS R37 DA015612
6 · The paper itself

Abstract

Network modelling is a valuable tool for simulating hepatitis C virus (HCV) and HIV transmission among people who inject drugs (PWID) and assessing the potential impact of treatment and harm-reduction interventions. In this paper, we review literature on network simulation models, highlighting key structural considerations and questions that network models are well suited to address. We describe five approaches (Erdös-Rényi, Stochastic Block, Watts-Strogatz, Barabási-Albert, and Exponential Random Graph Model) used to model partnership formation with emphasis on the strengths of each approach in simulating different features of real-world PWID networks. We also review two important structural considerations when designing or interpreting results from a network simulation study: (1) dynamic vs. static network and (2) injection only vs. both injection and sexual networks. Dynamic network simulations allow partnerships to evolve and disintegrate over time, capturing corresponding shifts in individual and population-level risk behaviour; however, their high level of complexity and reliance on difficult-to-observe data has driven others to develop static network models. Incorporating both sexual and injection partnerships increases model complexity and data demands, but more accurately represents HIV transmission between PWID and their sexual partners who may not also use drugs. Network models add the greatest value when used to investigate how leveraging network structure can maximize the effectiveness of health interventions and optimize investments. For example, network models have shown that features of a given network and epidemic influence whether the greatest community benefit would be achieved by allocating hepatitis C or HIV treatment randomly, versus to those with the most partners. They have also demonstrated the potential for syringe services and "buddy sharing" programs to reduce disease transmission.

Indexed as

Hepatitis CHIV InfectionsPharmaceutical PreparationsSubstance Abuse, IntravenousHepacivirusHumansRisk FactorsPharmaceutical PreparationsHepatitis CHIVNetwork modellingPeople who inject drugsReview

Identifiers

PMID31740175
PMCPMC8729792
OpenAlexW2984324285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.